ARS Pharmaceuticals (SPRY): A Bull Case Theory

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on SPRY. ARS Pharmaceuticals share was trading at $11.36 as of Sept 6.

A pharmacist in their lab coat preparing a drug-free nasal spray for distribution.

ARS Pharmaceuticals (SPRY) presents a compelling investment opportunity following the recent FDA approval of Neffy, its epinephrine nasal spray designed to disrupt the $1...